Develops therapeutic product candidates for inflammation and immuno-oncology. Focuses on antibody-based therapies, including Imsidolimab, Rosnilimab, and ANB032. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 39% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 23% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 39% a year on average.
Sales run at $234.6M a year. A small number, but proof the product has real buyers.
There is $311.6M in the vault; even if every debt were paid off, $297.5M would remain.
A loss of $13.2M against $234.6M in annual sales.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 34/100.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, ANAB sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ANAB is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (34/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.